The FTC and state attorneys general have accused Martin Shkreli of violating his lifetime industry ban by actively trading pharmaceutical stocks and influencing company management through public commentary. The enforcement action stems from a pattern of conduct documented across multiple livestreams and social media activity since his release from prison. FTC Commissioner Mark Meador emphasized that the ban remains only effective if breaches are met with consequences commensurate with the seriousness of the order.
In a public response, Shkreli expressed surprise at the filing, commenting on the perceived double standards between state attorneys general and the federal agency. The FTC's brief outlines four distinct phases of alleged violations, beginning with a 2022 trading competition and escalating to a recent $10,000,000 trading challenge launched in June 2026. During these streams, Shkreli was observed showing his accounts on screen, discussing pharmaceutical stocks at length, and predicting clinical trial outcomes.
Notably, in 2025, he claimed to possess a "magic trick" allowing him to profit regardless of trades made, and later advised viewers to short a specific pharmaceutical company, whose stock price subsequently dropped 17 percent. The agencies argue the stocks discussed represent merely the "tip of the iceberg," suggesting broader undisclosed activity. FTC staff reviewed only a fraction of Shkreli's social media footprint, with the defendant joking that he possessed other accounts undisclosed to investigators.
Source: Ars Technica · Summarized by HeadlinesBriefing